We use cookies for a better user experience. Read our Privacy Policy

I Agree

Advanced Glycation End Products Market Insights, 2021-2031

Advanced Glycation End Products Market (Type: Non-fluorescent AGEs and Fluorescent AGEs; Application: Diabetes Complications, Cancer, Bone Diseases, Neurodegenerative Diseases, and Others; and End User: Hospitals, Specialty Clinics, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

Patients with High sRAGE Levels at Risk for COVID-19 Morbidities

The coronavirus disease with lung involvement is being associated with frequent morbidity and mortality. Since the receptor for advanced glycation end product (RAGE) pathway is considered as one of the most important determinants of physiological aging, healthcare companies are increasing the availability of treatment options. The RAGE pathway is considered to play an important role in the physiological aging and pathogenesis of lung diseases. This is creating revenue opportunities for stakeholders in the advanced glycation end products market.

It has been found that patients with high serum soluble-RAGE (sRAGE) levels are more likely to be exposed to COVID-19. Such findings are helping healthcare companies in the advanced glycation end products market to keep their economies running amid the ongoing pandemic due to the demand for treatment options. The availability of treatment products is important since the RAGE pathways play an important role in aggravation of COVID-19 in patients.

advanced glycation end products market infographic

To know the scope of our report Get a Sample on Advanced Glycation End Products Market

Stakeholders Focus on Treatments for CHC Patients

Advanced glycation end products (AGEs) is found to be involved in the pathogenesis of various diseases. AGEs play a critical role in the fibrosis and cirrhosis of CHC (chronic hepatitis C) patients through autophagy induction and hepatic stellate cells (HSC) activation. Since this process generates irreversible glycation end products, it induces cellular anomalies that result in potentially fatal clinical consequences. Such findings are translating into incremental opportunities for stakeholders in the advanced glycation end products market.

The glycation reaction in CHC patients tends to activate multiple cellular signals through different receptors, while their toxic by-products lead to acceleration of the pathogenesis of many disorders. Hence, stakeholders in the advanced glycation end products market are increasing their focus in treatments for CHC patients.

Get a glimpse of the in-depth analysis through our Report Brochure

AGE-Alcohol-Adduct Formations in Patients Create Revenue Opportunities for Healthcare Providers

Alcohol is one of the most addictive substances consumed by billions of people and its excessive consumption has resulted in several diseases and injuries. However, there is lack of research pertaining the molecular mechanisms by which alcohol abuse causes cellular toxicity and organ damage. Hence, stakeholders in the advanced glycation end products market are increasing their R&D capabilities to derive the biological connection of AGE-alcohol-adduct formations to alcohol-mediated tissue injury.

Healthcare providers in hospitals, specialty clinics, and other facilities are helping patients to reduce the amounts of potentially harmful AGEs by decreasing the production of endogenous AGEs to prevent the possibility of several diseases. Since AGE adducts lead to alcohol-mediated multiorgan damage, stakeholders in the advanced glycation end products market are recommending patients to decrease the intake of n-6 fatty acids through dairy products, Western diets, and soft drinks, among others.

High Prevalence of Diabetes in Individuals Drives Global Market

The advanced glycation end products market is projected to reach US$ 2.76 Bn by 2031. The high prevalence of type 1 and type 2 diabetes is acting as one of the key drivers for market growth. As such, ELISA and spectrofluorimetric methods are being used to determine the concentration of different AGEs and their receptors amongst diabetes patients. These methods are being used to study protein-bound AGEs, fluorescent low molecular weight AGEs and new class of melibiose-derived glycation product (MAGE).

Diabetes is directly related to the increasing prevalence of overweight and obese patients. Hence, stakeholders in the advanced glycation end products market are creating awareness about HbA1c as an important segment of long-term glycemic control and a reliable biomarker for the diagnosis of diabetes.

R&D Helps Gain Insights in Stem Cell-based Regenerative Therapies

Stem cell-based regenerative therapies hold promising potentials for the treatment of a wide spectrum of diseases. However, it has been found that stem cell engraftment and survival are still challenging due to an unfavorable transplantation environment. Moreover, AGEs can add to the generation of these harmful conditions. Stakeholders in the advanced glycation end products market are increasing efforts to investigate solid scientific proof to derive new therapeutic insights into stem cell transplantation as an effective regenerative therapy.

It has been found that AGEs impair the proliferation and apoptosis on different types of primary stem cells in vitro. Stakeholders in the advanced glycation end products market are boosting their R&D capabilities to understand the effects of AGEs such as activation of RAGE or apoptopic pathways and even excessive ROS generation.

AGE Accumulation in Neuromusculoskeletal Tissues Triggers Demand for Treatment Options

Diabetic and elderly patients often have musculoskeletal disorders that are linked with AGEs. Such findings are bolstering research activities in the advanced glycation end products market, as AGEs are a biomarker for ageing and evaluating disease conditions. However, apart from fluorescence, spectroscopy and immunological methods used to measure AGEs, there is a need for more standardized evaluation methods due to the heterogeneity of AGEs. Stakeholders in the market are increasing their research to improve these evaluation methods.

The AGE accumulation in neuromusculoskeletal tissues, including muscles, bones, and cartilages, among others tend to adversely affect biomechanical properties by causing charge changes and forming cross-linkages. Such findings are compelling stakeholders in the advanced glycation end products market to increase the availability of treatment options for patients with musculoskeletal disorders.

Stakeholders Developing Strategies to Target Formation of AGEs in Vivo

AGEs accumulate in vivo and activate various signaling pathways closely related to the occurrence of various chronic metabolic diseases. The high prevalence of these diseases are contributing to the growth of the advanced glycation end products market. AGEs play a pathological role in the development of metabolic diseases such as diabetes, Alzheimer’s, and atherosclerosis, among others. Hence, stakeholders in the market are providing treatments that help to reduce the endogenous formation and accumulation in vivo to prevent and control diabetes.

Companies in the advanced glycation end products market are developing strategies to target the formation of AGEs in vivo. They are increasing awareness about metformin that helps to reduce blood glucose levels and induces glyoxalase I activity, which ultimately reduces the level of methylglyoxal (MG), an important precursor of AGEs.

advanced glycation end products market segmentation

Expanding operations in future? To get the perfect launch ask for a custom report

Analysts’ Viewpoint

Since the interaction of AGEs and their receptors (RAGE) cause inflammatory reactions and formation of blood clots in the walls of patients’ arteries, there is a need to improve effectiveness of treatments amid the COVID-19 pandemic. The advanced glycation end products market is predicted to expand at a CAGR of 5.4% during the forecast period. This is evident since there is a need for standardized evaluation methods to measure AGEs in patients with musculoskeletal disorders. Hence, stakeholders should increase efforts to understand AGEs related pathomechanism, which holds potential to develop novel methods for the prevention and therapy of such disorders that can affect patients’ quality of life.

Advanced Glycation End Products Market: Overview

  • Advanced glycation end products (AGEs) are a group of compounds that are usually developed via non-enzymatic reactions that occur between the carbonyl groups of reducing sugars & the free lipids, amino groups of proteins, or nucleic acids. They could be derived exogenously from diet or by endogenously inside the body. Advanced glycation end products form intracellular and extracellular inside every tissues and body fluids and are capable of cross-linking with other proteins, which can affect their normal mechanism or functions.
  • Aging is the progressive accumulation of damage to an organism over time, leading to disease and death. Recently, advanced glycation end products (AGEs) have received particular attention. AGEs are formed in high amounts in diabetes, but also in the physiological organism during aging.
  • AGEs seem to widely accumulate in extrinsically aged skin. The role of advanced glycation end products (AGEs) has been increasingly discussed in skin aging, and the potential of anti-AGE strategies has received high interest from pharmaceutical companies for the development of novel anti-aging cosmeceuticals compounds.
  • In the skin, glycation accounts for accelerated aging, yellowing and stiffness, and decreased circulation. Skin cannot look young and healthy with glycation products and treatment is best started with prevention by diet control, reducing total calories, and avoiding high sugar foods. However, supplements such as aminogua­nidine, pyridoxamine, carnosine, and benfotiamine are excellent glycation preventers and are already gaining traction in the cosmetic industry. As noted, topical products to treat glycation thus far are few and not very effective; however, a recent approach measuring Pentosidine in the skin suggests a new approach to skin care and anti-aging treatments.
  • Rising incidence of cancer globally is driving the market, as advanced glycation end products majorly raise the level of inflammation in the body, which has been associated with the development of cancer. For instance, according to the National Cancer Institute, 2019, an estimated 1,762,450 new cases of cancer were diagnosed globally, with around 606,880 deaths from the disease.
  • Rising incidences of neurodegenerative disorders including Alzheimer’s, Parkinson’s diseases, etc. is anticipated to fuel the market during the forecast period, as advanced glycation end products are proteins that get glycated after exposure to sugars, which further contributes to the development of neurodegenerative disorders. 

Market Segmentation: Advanced Glycation End Products Market

  • In terms of type, the global advanced glycation end products market has been classified into non-fluorescent AGEs, fluorescent AGEs, and others. The fluorescent AGEs segment can be further sub-segmented into Pentosidine and Methylglyoxal-lysine dimer (MOLD). The non-fluorescent AGEs segment can be further split into Carboxymethyl-lysine (CML), Carboxyethyl-lysine (CEL), and Pyrraline.
  • Based on application, the global advanced glycation end products market has been categorized into diabetes complications, cancer, bone diseases, neurodegenerative diseases, and others
  • In terms of end user, the global advanced glycation end products market has been classified into hospitals, specialty clinics, and others
  • Each of the segments has been analyzed in detail for market trends, recent trends, and developments, drivers, restraints, opportunities, and useful insights. The advanced glycation end products market report provides current and expected revenue (US$ Mn) for each of these segments from 2021 to 2031, considering 2020 as the base year. The compound annual growth rate (percentage CAGR) has been provided for each segment and market from 2021 to 2031, along with market size estimations.

Regional Overview: Advanced Glycation End Products Market

  • In terms of region, the global advanced glycation end products market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been divided into major countries and sub-regions.
  • Rise in prevalence of lifestyle diseases and increase in healthcare expenditure are anticipated to boost the market in North America during the forecast period. According to the Centers for Disease Control and Prevention, presently, over 100 million adults in the U.S. are living with diabetes or prediabetes. About 1.4 million new cases of diabetes are diagnosed in the U.S. every year. More than one in every 10 adults aged 20 or older has diabetes.
  • The market in Latin America is projected to expand at a steady pace, owing to the presence of rapidly developing economies, along with enhanced healthcare infrastructure in the region. The market in Brazil is anticipated to expand at a significant growth rate during the forecast period due to the rising life science-regarding research and development of healthcare infrastructure in the country.
  • The current and expected market revenue (US$ Mn) of these regional markets and their major countries have been provided in the report from 2021 to 2031, with their CAGRs from 2021 to 2031
  • The study also offers a list of recommendations, highlights, and useful insights of the global advanced glycation end products market, which would help new companies willing to enter the market and existing companies to increase market shares and in the decision-making process

Major Players

  • The advanced glycation end products market report concludes with the company profiles section, which includes key information about major players in the global advanced glycation end products market
  • Leading players analyzed in the report include
    • AbbVie, Inc. (Allergan Plc)
    • Merck KGaA
    • Takeda Pharmaceutical Company Limited
    • Estée Lauder Companies
    • Shiseido Company, Limited
    • Beiersdorf AG
    • L’Oreal S.A.
    • NuFACE
    • Rodan & Fields
    • PhotoMedex, Inc.
    • Ostium Cosmetics
    • Cell Biolabs, Inc.
    • Shanghai Korain Biotech Co., Ltd.
  • Each of these players has been profiled in the advanced glycation end products market report based on parameters such as company overview, financial overview, business strategies, application portfolio, business segments, and recent developments

Advanced Glycation End Products Market – Segmentation

TMR’s study on the global advanced glycation end products market includes information divided into four segments: type, application, end user, and region. Changing industry trends and other crucial market dynamics associated with these segments of the global advanced glycation end products market are discussed in detail.

Type
  • Non-fluorescent AGEs
  • Fluorescent AGEs
Application
  • Diabetic Complications
  • Cancer
  • Bone Diseases
  • Neurodegenerative Diseases
  • Others
End User
  • Hospitals
  • Specialty Clinics
  • Others
Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Interested in this report?
Get a FREE sample now!

Get Free Sample

*Get Sample Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the total market worth of advanced glycation end products market?

Advanced glycation end products market to reach valuation Of US$ 2.76 Bn by 2031

What is the anticipated CAGR of the advanced glycation end products market in the forecast period?

Advanced glycation end products market is projected to expand at a CAGR of 5.4% from 2021 to 2031

What are the key driving factors for the growth of the advanced glycation end products market?

Advanced glycation end products market is driven by high prevalence of diabetes in individuals

Which is the rising prominent segment in the advanced glycation end products market?

The non-fluorescent AGEs segment dominated the global advanced glycation end products market and the trend is likely to continue during the forecast period.

Who are the key players in the global advanced glycation end products market?

Key players operating in the global advanced glycation end products market include AbbVie, Inc. (Allergan Plc), Merck KGaA, Takeda Pharmaceutical Company Limited, Estée Lauder Companies, Shiseido Company

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Advanced Glycation End Products Market

4. Market Overview

    4.1. Introduction

        4.1.1. Type Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Advanced Glycation End Products Market Analysis and Forecast, 2017–2031

5. Key Insights

    5.1. Bioactivity of AGEs and RAGE: Flowchart

    5.2. Key Trend Analysis

    5.3. COVID-19 Pandemic Impact on Industry (Value Chain and Short / Mid / Long Term Impact)

6. Global Advanced Glycation End Products Market Analysis and Forecast, by Type

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Global Advanced Glycation End Products Market Value Forecast, by Type, 2017–2031

        6.3.1. Non-fluorescent AGEs

            6.3.1.1. Carboxymethyl-lysine (CML)

            6.3.1.2. Carboxyethyl-lysine (CEL)

            6.3.1.3. Pyrraline

        6.3.2. Fluorescent AGEs

            6.3.2.1. Pentosidine

            6.3.2.2. Methylglyoxal-lysine dimer (MOLD)

    6.4. Global Advanced Glycation End Products Market Attractiveness, by Type

7. Global Advanced Glycation End Products Market Analysis and Forecast, by Application

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Global Advanced Glycation End Products Market Value Forecast, by Application, 2017–2031

        7.3.1. Diabetic Complications

        7.3.2. Cancer

        7.3.3. Bone Diseases

        7.3.4. Neurodegenerative Diseases

        7.3.5. Others

    7.4. Global Advanced Glycation End Products Market Attractiveness, by Application

8. Global Advanced Glycation End Products Market Analysis and Forecast, by End-user

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Global Advanced Glycation End Products Market Value Forecast, by End-user, 2017–2031

        8.3.1. Hospitals

        8.3.2. Specialty Clinics

        8.3.3. Others

    8.4. Global Advanced Glycation End Products Market Attractiveness, by End-user

9. Global Advanced Glycation End Products Market Analysis and Forecast, by Region

    9.1. Key Findings

    9.2. Global Advanced Glycation End Products Market Value Forecast, by Region

        9.2.1. North America

        9.2.2. Europe

        9.2.3. Asia Pacific

        9.2.4. Latin America

        9.2.5. Middle East & Africa

    9.3. Global Advanced Glycation End Products Market Attractiveness, by Country/Region

10. North America Advanced Glycation End Products Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. North America Advanced Glycation End Products Market Value Forecast, by Type, 2017–2031

        10.2.1. Non-fluorescent AGEs

            10.2.1.1. Carboxymethyl-lysine (CML)

            10.2.1.2. Carboxyethyl-lysine (CEL)

            10.2.1.3. Pyrraline

        10.2.2. Fluorescent AGEs

            10.2.2.1. Pentosidine

            10.2.2.2. Methylglyoxal-lysine dimer (MOLD)

    10.3. North America Advanced Glycation End Products Market Value Forecast, by Application, 2017–2031

        10.3.1. Diabetic Complications

        10.3.2. Cancer

        10.3.3. Bone Diseases

        10.3.4. Neurodegenerative Diseases

        10.3.5. Others

    10.4. North America Advanced Glycation End Products Market Value Forecast, by End-user, 2017–2031

        10.4.1. Hospitals

        10.4.2. Specialty Clinics

        10.4.3. Others

    10.5. North America Advanced Glycation End Products Market Value Forecast, by Country, 2017–2031

        10.5.1. U.S.

        10.5.2. Canada

    10.6. North America Advanced Glycation End Products Market Attractiveness Analysis

        10.6.1. By Type

        10.6.2. By Application

        10.6.3. By End-user

        10.6.4. By Country

11. Europe Advanced Glycation End Products Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Europe Advanced Glycation End Products Market Value Forecast, by Type, 2017–2031

        11.2.1. Non-fluorescent AGEs

            11.2.1.1. Carboxymethyl-lysine (CML)

            11.2.1.2. Carboxyethyl-lysine (CEL)

            11.2.1.3. Pyrraline

        11.2.2. Fluorescent AGEs

            11.2.2.1. Pentosidine

            11.2.2.2. Methylglyoxal-lysine dimer (MOLD)

    11.3. Europe Advanced Glycation End Products Market Value Forecast, by Application, 2017–2031

        11.3.1. Diabetic Complications

        11.3.2. Cancer

        11.3.3. Bone Diseases

        11.3.4. Neurodegenerative Diseases

        11.3.5. Others

    11.4. Europe Advanced Glycation End Products Market Value Forecast, by End-user, 2017–2031

        11.4.1. Hospitals

        11.4.2. Specialty Clinics

        11.4.3. Others

    11.5. Europe Advanced Glycation End Products Market Value Forecast, by Country/Sub-region, 2017–2031

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Spain

        11.5.5. Italy

        11.5.6. Rest of Europe

    11.6. Europe Advanced Glycation End Products Market Attractiveness Analysis

        11.6.1. By Type

        11.6.2. By Application

        11.6.3. By End-user

        11.6.4. By Country/Sub-region

12. Asia Pacific Advanced Glycation End Products Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Asia Pacific Advanced Glycation End Products Market Value Forecast, by Type, 2017–2031

        12.2.1. Non-fluorescent AGEs

            12.2.1.1. Carboxymethyl-lysine (CML)

            12.2.1.2. Carboxyethyl-lysine (CEL)

            12.2.1.3. Pyrraline

        12.2.2. Fluorescent AGEs

            12.2.2.1. Pentosidine

            12.2.2.2. Methylglyoxal-lysine dimer (MOLD)

    12.3. Asia Pacific Advanced Glycation End Products Market Value Forecast, by Application, 2017–2031

        12.3.1. Diabetic Complications

        12.3.2. Cancer

        12.3.3. Bone Diseases

        12.3.4. Neurodegenerative Diseases

        12.3.5. Others

    12.4. Asia Pacific Advanced Glycation End Products Market Value Forecast, by End-user, 2017–2031

        12.4.1. Hospitals

        12.4.2. Specialty Clinics

        12.4.3. Others

    12.5. Asia Pacific Advanced Glycation End Products Market Value Forecast, by Country/Sub-region, 2017–2031

        12.5.1. China

        12.5.2. Japan

        12.5.3. India

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific

    12.6. Asia Pacific Advanced Glycation End Products Market Attractiveness Analysis

        12.6.1. By Type

        12.6.2. By Application

        12.6.3. By End-user

        12.6.4. By Country/Sub-region

13. Latin America Advanced Glycation End Products Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Latin America Advanced Glycation End Products Market Value Forecast, by Type, 2017–2031

        13.2.1. Non-fluorescent AGEs

            13.2.1.1. Carboxymethyl-lysine (CML)

            13.2.1.2. Carboxyethyl-lysine (CEL)

            13.2.1.3. Pyrraline

        13.2.2. Fluorescent AGEs

            13.2.2.1. Pentosidine

            13.2.2.2. Methylglyoxal-lysine dimer (MOLD)

    13.3. Latin America Advanced Glycation End Products Market Value Forecast, by Application, 2017–2031

        13.3.1. Diabetic Complications

        13.3.2. Cancer

        13.3.3. Bone Diseases

        13.3.4. Neurodegenerative Diseases

        13.3.5. Others

    13.4. Latin America Advanced Glycation End Products Market Value Forecast, by End-user, 2017–2031

        13.4.1. Hospitals

        13.4.2. Specialty Clinics

        13.4.3. Others

    13.5. Latin America Advanced Glycation End Products Market Value Forecast, by Country/Sub-region, 2017–2031

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America

    13.6. Latin America Advanced Glycation End Products Market Attractiveness Analysis

        13.6.1. By Type

        13.6.2. By Application

        13.6.3. By End-user

        13.6.4. By Country/Sub-region

14. Middle East & Africa Advanced Glycation End Products Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Middle East & Africa Advanced Glycation End Products Market Value Forecast, by Type, 2017–2031

        14.2.1. Non-fluorescent AGEs

            14.2.1.1. Carboxymethyl-lysine (CML)

            14.2.1.2. Carboxyethyl-lysine (CEL)

            14.2.1.3. Pyrraline

        14.2.2. Fluorescent AGEs

            14.2.2.1. Pentosidine

            14.2.2.2. Methylglyoxal-lysine dimer (MOLD)

    14.3. Middle East & Africa Advanced Glycation End Products Market Value Forecast, by Application, 2017–2031

        14.3.1. Diabetic Complications

        14.3.2. Cancer

        14.3.3. Bone Diseases

        14.3.4. Neurodegenerative Diseases

        14.3.5. Others

    14.4. Middle East & Africa Advanced Glycation End Products Market Value Forecast, by End-user, 2017–2031

        14.4.1. Hospitals

        14.4.2. Specialty Clinics

        14.4.3. Others

    14.5. Middle East & Africa Advanced Glycation End Products Market Value Forecast, by Country/Sub-region, 2017–2031

        14.5.1. GCC Countries

        14.5.2. South Africa

        14.5.3. Rest of Middle East & Africa

    14.6. Middle East & Africa Advanced Glycation End Products Market Attractiveness Analysis

        14.6.1. By Type

        14.6.2. By Application

        14.6.3. By End-user

        14.6.4. By Country/Sub-region

15. Competition Landscape

    15.1. Market Share Analysis, by Company (2020)

    15.2. Company Profiles

        15.2.1. AbbVie, Inc. (Allergan Plc)

            15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.1.2. Company Financials

            15.2.1.3. Growth Strategies

            15.2.1.4. SWOT Analysis

        15.2.2. Merck KGaA

            15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.2.2. Company Financials

            15.2.2.3. Growth Strategies

            15.2.2.4. SWOT Analysis

        15.2.3. Takeda Pharmaceutical Company Limited

            15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.3.2. Company Financials

            15.2.3.3. Growth Strategies

            15.2.3.4. SWOT Analysis

        15.2.4. Estée Lauder Companies

            15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.4.2. Company Financials

            15.2.4.3. Growth Strategies

            15.2.4.4. SWOT Analysis

        15.2.5. Shiseido Company, Limited

            15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.5.2. Company Financials

            15.2.5.3. Growth Strategies

            15.2.5.4. SWOT Analysis

        15.2.6. Beiersdorf AG

            15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.6.2. Company Financials

            15.2.6.3. Growth Strategies

            15.2.6.4. SWOT Analysis

        15.2.7. L'Oréal S.A.

            15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.7.2. Company Financials

            15.2.7.3. Growth Strategies

            15.2.7.4. SWOT Analysis

        15.2.8. NuFACE

            15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.8.2. Company Financials

            15.2.8.3. Growth Strategies

            15.2.8.4. SWOT Analysis

        15.2.9. Rodan & Fields

            15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.9.2. Company Financials

            15.2.9.3. Growth Strategies

            15.2.9.4. SWOT Analysis

        15.2.10. PhotoMedex, Inc.

            15.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.10.2. Company Financials

            15.2.10.3. Growth Strategies

            15.2.10.4. SWOT Analysis

        15.2.11. Ostium Cosmetics

            15.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.11.2. Company Financials

            15.2.11.3. Growth Strategies

            15.2.11.4. SWOT Analysis

        15.2.12. Cell Biolabs, Inc.

            15.2.12.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.12.2. Company Financials

            15.2.12.3. Growth Strategies

            15.2.12.4. SWOT Analysis

        15.2.13. Shanghai Korain Biotech Co., Ltd.

            15.2.13.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.2.13.2. Company Financials

            15.2.13.3. Growth Strategies

            15.2.13.4. SWOT Analysis

List of Tables

Table 01: Global Advanced Glycation End Products Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 02: Global Advanced Glycation End Products Market Volume (Units) Forecast, by Non-fluorescent AGEs Type, 2017–2031

Table 03: Global Advanced Glycation End Products Market Volume (Units) Forecast, by Fluorescent AGEs Type, 2017–2031

Table 04: Global Advanced Glycation End Products Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 05: Global Advanced Glycation End Products Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 06: Global Advanced Glycation End Products Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 07: North America Advanced Glycation End Products Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 08: North America Advanced Glycation End Products Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 09: North America Advanced Glycation End Products Market Volume (Units) Forecast, by Non-fluorescent AGEs Type, 2017–2031

Table 10: North America Advanced Glycation End Products Market Volume (Units) Forecast, by Fluorescent AGEs Type, 2017–2031

Table 11: North America Advanced Glycation End Products Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 12: North America Advanced Glycation End Products Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 13: Europe Advanced Glycation End Products Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 14: Europe Advanced Glycation End Products Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 15: Europe Advanced Glycation End Products Market Volume (Units) Forecast, by Non-fluorescent AGEs Type, 2017–2031

Table 16: Europe Advanced Glycation End Products Market Volume (Units) Forecast, by Fluorescent AGEs Type, 2017–2031

Table 17: Europe Advanced Glycation End Products Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 18: Europe Advanced Glycation End Products Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 19: Asia Pacific Advanced Glycation End Products Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 20: Asia Pacific Advanced Glycation End Products Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 21: Asia Pacific Advanced Glycation End Products Market Volume (Units) Forecast, by Non-fluorescent AGEs Type, 2017–2031

Table 22: Asia Pacific Advanced Glycation End Products Market Volume (Units) Forecast, by Fluorescent AGEs Type, 2017–2031

Table 23: Asia Pacific Advanced Glycation End Products Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 24: Asia Pacific Advanced Glycation End Products Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 25: Latin America Advanced Glycation End Products Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 26: Latin America Advanced Glycation End Products Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 27: Latin America Advanced Glycation End Products Market Volume (Units) Forecast, by Non-fluorescent AGEs Type, 2017–2031

Table 28: Latin America Advanced Glycation End Products Market Volume (Units) Forecast, by Fluorescent AGEs Type, 2017–2031

Table 29: Latin America Advanced Glycation End Products Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 30: Latin America Advanced Glycation End Products Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 31: Middle East & Africa Advanced Glycation End Products Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 32: Middle East & Africa Advanced Glycation End Products Market Value (US$ Mn) Forecast, by Type, 2017–2031

Table 33: Middle East & Africa Advanced Glycation End Products Market Volume (Units) Forecast, by Non-fluorescent AGEs Type, 2017–2031

Table 34: Middle East & Africa Advanced Glycation End Products Market Volume (Units) Forecast, by Fluorescent AGEs Type, 2017–2031

Table 35: Middle East & Africa Advanced Glycation End Products Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 36: Middle East & Africa Advanced Glycation End Products Market Value (US$ Mn) Forecast, by End-user, 2017–2031

List of Figures

Figure 01: Global Advanced Glycation End Products Market Value (US$ Mn) and Y-O-Y Growth (%) Forecast, 2017–2031

Figure 02: Global Advanced Glycation End Products Market Value Share, by Region, 2020

Figure 03: Global Advanced Glycation End Products Market Value Share Analysis, by Type, 2020 and 2031

Figure 04: Global Advanced Glycation End Products Market Value (US$ Mn), Non-fluorescent AGEs, 2017–2031

Figure 05: Global Advanced Glycation End Products Market Value (US$ Mn), Fluorescent AGEs, 2017–2031

Figure 06: Global Advanced Glycation End Products Market Attractiveness Analysis, by Type, 2021-2031

Figure 07: Global Advanced Glycation End Products Market Value Share Analysis, by Application, 2020 and 2031

Figure 08: Global Advanced Glycation End Products Market Value (US$ Mn), by Diabetic Complications, 2017–2031

Figure 09: Global Advanced Glycation End Products Market Value (US$ Mn), Cancer, 2017–2031

Figure 10: Global Advanced Glycation End Products Market Value (US$ Mn), by Bone Diseases, 2017–2031

Figure 11: Global Advanced Glycation End Products Market Value (US$ Mn), Neurodegenerative Diseases, 2017–2031

Figure 12: Global Advanced Glycation End Products Market Value (US$ Mn), by Others, 2017–2031

Figure 13: Global Advanced Glycation End Products Market Attractiveness Analysis, by Application, 2021–2031

Figure 14: Global Advanced Glycation End Products Market Value Share Analysis, by End-user, 2020 and 2031

Figure 15: Global Advanced Glycation End Products Market Value (US$ Mn), by Hospitals, 2017–2031

Figure 16: Global Advanced Glycation End Products Market Value (US$ Mn), Specialty Clinics , 2017–2031

Figure 17: Global Advanced Glycation End Products Market Value (US$ Mn), by Others, 2017–2031

Figure 18: Global Advanced Glycation End Products Market Attractiveness Analysis, by End-user, 2021–2031

Figure 19: Global Advanced Glycation End Products Market Value Share Analysis, by Region, 2020 and 2031

Figure 20: Global Advanced Glycation End Products Market Attractiveness Analysis, by Region

Figure 21: North America Advanced Glycation End Products Market Value (US$ Mn) Forecast Projection, 2017–2031

Figure 22: North America Advanced Glycation End Products Market Value Share (%), by Country, 2020 and 2031

Figure 23: North America Advanced Glycation End Products Market Attractiveness, by Country, 2021–2031

Figure 24: North America Advanced Glycation End Products Market Value Share Analysis, by Type, 2020 and 2031

Figure 25: North America Advanced Glycation End Products Market Attractiveness, by Type, 2021–2031

Figure 26: North America Advanced Glycation End Products Market Value Share Analysis, by Application, 2020 and 2031

Figure 27: North America Advanced Glycation End Products Market Attractiveness, by Application, 2021–2031

Figure 28: North America Advanced Glycation End Products Market Value Share Analysis, by End-user, 2020 and 2031

Figure 29: North America Advanced Glycation End Products Market Attractiveness, by End-user, 2021–2031

Figure 30: Europe Advanced Glycation End Products Market Value (US$ Mn) Forecast Projection, 2017–2031

Figure 31: Europe Advanced Glycation End Products Market Value Share (%), by Country/Sub-region, 2020 and 2031

Figure 32: Europe Advanced Glycation End Products Market Attractiveness, by Country/Sub-region, 2021–2031

Figure 33: Europe Advanced Glycation End Products Market Value Share Analysis, by Type, 2020 and 2031

Figure 34: Europe Advanced Glycation End Products Market Attractiveness, by Type, 2021–2031

Figure 35: Europe Advanced Glycation End Products Market Value Share Analysis, by Application, 2020 and 2031

Figure 36: Europe Advanced Glycation End Products Market Attractiveness, by Application, 2021–2031

Figure 37: Europe Advanced Glycation End Products Market Value Share Analysis, by End-user, 2020 and 2031

Figure 38: Europe Advanced Glycation End Products Market Attractiveness, by End-user, 2021–2031

Figure 39: Asia Pacific Advanced Glycation End Products Market Value (US$ Mn) Forecast Projection, 2017–2031

Figure 40: Asia Pacific Advanced Glycation End Products Market Value Share (%), by Country, 2020 and 2031

Figure 41: Asia Pacific Advanced Glycation End Products Market Attractiveness, by Country/Sub-region, 2021–2031

Figure 42: Asia Pacific Advanced Glycation End Products Market Value Share Analysis, by Type, 2020 and 2031

Figure 43: Asia Pacific Advanced Glycation End Products Market Attractiveness, by Type, 2021–2031

Figure 44: Asia Pacific Advanced Glycation End Products Market Value Share Analysis, by Application, 2020 and 2031

Figure 45: Asia Pacific Advanced Glycation End Products Market Attractiveness, by Application, 2021–2031

Figure 46: Asia Pacific Advanced Glycation End Products Market Value Share Analysis, by End-user, 2020 and 2031

Figure 47: Asia Pacific Advanced Glycation End Products Market Attractiveness, by End-user, 2021–2031

Figure 48: Latin America Advanced Glycation End Products Market Revenue (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 49: Latin America Advanced Glycation End Products Market Value Share (%), by Country/Sub-region, 2020 and 2031

Figure 50: Latin America Advanced Glycation End Products Market Attractiveness, by Country, 2021–2031

Figure 51: Latin America Advanced Glycation End Products Market Value Share Analysis, by Type, 2020 and 2031

Figure 52: Latin America Advanced Glycation End Products Market Attractiveness, by Type, 2021–2031

Figure 53: Latin America Advanced Glycation End Products Market Value Share Analysis, by Application, 2020 and 2031

Figure 54: Latin America Advanced Glycation End Products Market Attractiveness, by Application, 2021–2031

Figure 55: Latin America Advanced Glycation End Products Market Value Share Analysis, by End-user, 2020 and 2031

Figure 56: Latin America Advanced Glycation End Products Market Attractiveness, by End-user, 2021–2031

Figure 57: Middle East & Africa Advanced Glycation End Products Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 58: Middle East & Africa Advanced Glycation End Products Market Value Share, by Country/Sub-region, 2020–2031

Figure 59: Middle East & Africa Advanced Glycation End Products Market Attractiveness, by Country/Sub-region, 2021–2031

Figure 60: Middle East & Africa Advanced Glycation End Products Market Value Share Analysis, by Type, 2020 and 2031

Figure 61: Middle East & Africa Advanced Glycation End Products Market Attractiveness, by Type, 2021–2031

Figure 62: Middle East & Africa Advanced Glycation End Products Market Value Share Analysis, by Application, 2020 and 2031

Figure 63: Middle East & Africa Advanced Glycation End Products Market Attractiveness, by Application, 2021–2031

Figure 64: Middle East & Africa Advanced Glycation End Products Market Value Share Analysis, by End-user, 2020 and 2031

Figure 65: Middle East & Africa Advanced Glycation End Products Market Attractiveness, by End-user, 2021–2031

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

725

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved